Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.235 EUR | -0.15% | +0.78% | -8.62% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 171% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.62% | 173M | C- | ||
+25.69% | 47.86B | B- | ||
+46.90% | 41.42B | A | ||
-3.46% | 40.66B | B | ||
-6.20% | 28.92B | C | ||
+9.17% | 25.55B | B- | ||
-20.42% | 19.27B | B | ||
+0.17% | 12.15B | B+ | ||
+28.07% | 12.14B | C+ | ||
-1.24% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GNFT Stock
- Ratings GENFIT